This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
by Zacks Equity Research
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADXS) Outperforming Other Medical Stocks This Year?
Advaxis Up on Positive Early-Stage Immunotherapy Study Data
by Zacks Equity Research
Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Will Advaxis Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Advaxis.
Top Ranked Momentum Stocks to Buy for March 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 28th.
Top Ranked Momentum Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 27th:
Top Ranked Momentum Stocks to Buy for March 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th:
Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADXS) Outperforming Other Medical Stocks This Year?
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Advaxis (ADXS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Advaxis (ADXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Advaxis (ADXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Advaxis (ADXS) delivered earnings and revenue surprises of -107.14% and 2.64%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Advaxis (ADXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Bristol-Myers Partners Array to Investigate Cancer Candidate
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.